Biosimilars: Inverting the Innovator Development Model
This article was originally published in RPM Report
Executive Summary
When it comes to the new biosimilar pathway, it’s the IND—not the BLA—that matters.
You may also be interested in...
The Real ‘Pill Penalty’: US Biosimilar Law, Not The IRA
Biopharma industry is making some modest headway in quest to change the new US Medicare drug price process to treat drugs and biologics on equal footing. But eliminating the so-called ‘pill penalty’ would not on its own equalize the incentives for small molecule and large molecule R&D.
Words Of Wisdom For Biosimilar Developers
FDA has learned a lot from its biosimilar meetings and sponsor discussions so far – including the areas sponsors struggle with and how others might improve their understanding going forward.
Where Are The Biosimilars?
An abbreviated pathway for follow-on biologics was one of the biggest issues for biotech investors in the legislative debate over health care reform. Two years after enactment, FDA is still waiting for the first application.